The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

“Treatment-resistant depression can be very complicated ... symptom improvement,” the statement quoted Bill Martin of Johnson & Johnson and saying. “With Spravato now approved as a stand ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...